Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. - Wikidata - awgldk - TriplyDB

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

http://www.wikidata.org/entity/Q33839857

about

Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection Signal transduction in the chronic leukemias: implications for targeted therapies Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms Differential biological activity of disease-associated JAK2 mutants Mouse models of myeloproliferative neoplasms: JAK of all grades Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance Stem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry.Conditional disruption of interactions between Gαi2 and regulator of G protein signaling (RGS) proteins protects the heart from ischemic injury Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.AKT is a therapeutic target in myeloproliferative neoplasms Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.Generation and characterization of a JAK2V617F-containing erythroleukemia cell line.Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice.Development of a highly sensitive method for detection of JAK2V617F A truncation mutant of Csf3r cooperates with PML-RARα to induce acute myeloid leukemia in mice.A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.Critical requirement for Stat5 in a mouse model of polycythemia vera.Efficacy of vorinostat in a murine model of polycythemia vera Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis.Identification of AIM2 as a downstream target of JAK2V617F.

P2860

Q24607513-F36A2224-EB3E-49CF-9DE1-77C3799D93A9 Q27026031-AE14730E-A6D6-42C2-9E1A-3229E144793A Q27317353-483B6618-41DC-469A-989C-E17D6C440DD0 Q27687464-40048490-6EBB-470F-B0F5-F3757606455A Q28271752-A2C6964F-2055-4F65-8D2A-D5630D2D3C0F Q28508045-4EF2793C-CEAF-45FB-9894-55CBD1917111 Q28744478-2B2DB924-74D9-4024-B24E-C43763BBD782 Q30666276-F8D8D721-0590-4E9A-963E-AB7827C80522 Q31156217-1AA4EA79-92B1-4F17-A632-128CC85C85AD Q31162717-B464B764-9EBB-4AA6-A02F-D5836A107673 Q33419130-0373DB24-4E9B-4D5F-90FD-03A1650633CE Q33623277-14AE2685-A005-4D9F-8B2C-23C698FF4E43 Q33697252-E73C8C45-5315-4989-8687-DDBEA92BF8DF Q33798544-A4C9824E-A4F0-4106-A1D4-654883B3CBEB Q33921220-B5F0DA9F-9178-47B6-9615-A62AAD68EB42 Q33982315-E3F3194D-5069-4022-984C-9190071C640F Q33983970-CA961584-18CA-4E18-9366-1A41CBBF11D3 Q34182447-552C6F87-E22F-4EBA-9B9B-FC54696DB2F7 Q34375134-D386A410-984D-48AA-9089-3660FDE3E05E Q34378552-FD7B9A1C-095E-4797-9BBA-E423C10EA063 Q34471806-94EB3DC7-89F8-4DB7-A848-3802607782D1 Q34547493-BD2E4526-900F-43A8-8526-D01DE914073C Q34575726-8A7D58CA-3855-4F03-B89B-1DA600B208F0 Q34612536-D16817C3-86CE-4FAB-8618-81A6BA2BC9E9 Q34737531-FCF430D0-6203-46D7-9CE0-0A10A2097C01 Q34750582-E312EE7F-A27D-4EBE-B5DF-F7FCC2B91A56 Q35037403-1DB8FE6F-231A-4E32-8AFD-D6B5DB12641E Q35521645-1C8EE111-476A-4DF5-82B6-F1387CB88F00 Q35564931-C1F15FF2-E186-4BE9-A70F-79A1F368B6B9 Q35613434-A8AC6CDC-0A6F-4C73-9580-0454A4579ED4 Q35679582-56E231C2-19C6-458A-8539-DF9DB30B0B23 Q35885303-2F9FE0A0-CAA0-46FB-831F-D19E1658D457 Q35909673-7CEFEC32-1ECA-4A76-84E7-11E00F68C4BA Q36003480-ECE3B0C8-D6D3-4284-9FF4-E9DC38D11EC8 Q36079782-C57B3FCC-1372-4706-95A9-9F31244CBF9C Q36137458-167255A2-C492-4398-BA84-757053F141EF Q36206435-06F7294A-FC10-40C4-891C-B17D993B7CF1 Q36216237-B2814440-8901-41D7-BC03-3E04D83B522D Q36263805-81C778B4-CE82-47BB-AAEB-9701B9355169 Q36513561-4B2108CE-65D6-4900-9ED1-3556AD08C584

P2860

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

http://www.wikidata.org/entity/Q33839857

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Conditional expression of hete ...... olycythemia vera-like disease.

@ast

Conditional expression of hete ...... olycythemia vera-like disease.

@en

type

label

Conditional expression of hete ...... olycythemia vera-like disease.

@ast

Conditional expression of hete ...... olycythemia vera-like disease.

@en

prefLabel

Conditional expression of hete ...... olycythemia vera-like disease.

@ast

Conditional expression of hete ...... olycythemia vera-like disease.

@en

P1433

Q33839857-CDC35456-5760-4BE5-9097-AD1BC3D40C13

P1476

Q33839857-BBC91756-170C-41D4-8DAA-00A8E90F50A0

P2093

Q33839857-13CF1052-0E93-4426-A0A4-2E0A253DCB55

Q33839857-4BF6DEB1-8D3D-444B-892F-E4F6F1690B31

Q33839857-C10399DB-87A5-479B-B3B5-75CEDE06F6AD

Q33839857-CF603A47-8408-4B5B-949B-B94CEBCAC253

Q33839857-DE66A24D-AB9A-4164-8C5F-4567F0EF7979

Q33839857-EE5CFB1E-983E-4ABC-B997-F528278A213E

P2860

Q33839857-12553146-5B2A-4F0B-BBA6-8FD70236242D

Q33839857-1D52B4B8-F9D7-430A-B127-ED538EEAABF6

Q33839857-20035EEC-6D1D-4416-B500-82201B663989

Q33839857-2A47E9C5-C561-43E4-8F7A-418C4BBFA91C

Q33839857-2B988E51-4A0B-414B-AA96-BB0823863FAC

Q33839857-3274D4FE-1AA0-4B2C-86B0-7E48950963C6

Q33839857-34156767-04B4-492C-8B54-39CD4488B56A

Q33839857-4853542E-2B74-43DE-B5D7-061BEE768828

Q33839857-49C303B3-163B-4D27-8811-7D512A24F948

Q33839857-57A1F892-E0FC-4C7A-82C8-F28F099544E6

P304

Q33839857-631F12A3-5F0B-4271-8C1B-0C662E96FB6E

P31

Q33839857-28E4003A-F690-4588-809C-FF0013D7A182

P356

Q33839857-4030D661-EB65-432A-93A3-2D516E58FCA6

P407

Q33839857-55F792D9-2F4E-478F-B0F0-1830FCA1F11F

P433

Q33839857-63D74237-8550-4F29-8E6C-71DF805DC662

P478

Q33839857-DCCC87DB-39E1-4567-910C-957963589ACA

P577

Q33839857-05370060-6CB3-4881-8AAE-8D2EE2FA3C93

P5875

Q33839857-AE124671-A86D-4F32-8438-DC91D07FDF69

P698

Q33839857-D67ED2F4-C149-469E-8510-DC1CF4831167

P932

Q33839857-4E9A6304-B202-409A-9FB3-EC53B445133D

P356

BLOOD-2009-04-215848

P1433

P1476

Conditional expression of hete ...... olycythemia vera-like disease.

@en

P2093

Dongqing Yan

http://www.w3.org/2001/XMLSchema#string

Haiying Zou

http://www.w3.org/2001/XMLSchema#string

Hajime Akada

http://www.w3.org/2001/XMLSchema#string

M Golam Mohi

http://www.w3.org/2001/XMLSchema#string

Robert E Hutchison

http://www.w3.org/2001/XMLSchema#string

Steven Fiering

http://www.w3.org/2001/XMLSchema#string

P2860

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Jak2 is essential for signaling through a variety of cytokine receptors

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Inducible gene targeting in mice

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Identification of an acquired JAK2 mutation in polycythemia vera.

P304

3589-3597

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-04-215848

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41669371

http://www.w3.org/2001/XMLSchema#string

P698

20197548

http://www.w3.org/2001/XMLSchema#string

P932

2867267

http://www.w3.org/2001/XMLSchema#string